her2 low breast cancer a new therapeutic subtype | 2023 ku breast cancer year in review conference
Published 1 year ago • 2K plays • Length 25:20Download video MP4
Download video MP3
Similar videos
-
2:06
antibody-drug conjugates for her2-low disease: 2023 ku breast cancer year in review
-
26:08
metastatic hormone positive breast cancer | 2023 ku breast cancer year in review conference
-
5:19
historical perspective on hr /her2- breast cancer: 2023 ku breast cancer year in review
-
30:22
adjuvant therapy | 2023 ku breast cancer year in review conference
-
1:10
the evolution of her2-low-positive breast cancer as a clinical subtype
-
1:17
clinical outcomes in women with metastatic her2-low breast cancer in the real world
-
4:12
clinical implications of ‘low’ her2 expression: 2023 best of breast conference
-
6:29
hot topics in advanced breast cancer: 2023 best of breast conference
-
0:50
attend the 2023 breast cancer year in review | priyanka sharma, md & jennifer klemp, phd, mph, ma
-
2:43
sequencing treatment options in her2 positive breast cancer: 2023 best of breast conference
-
2:19
cdk 4/6 inhibitors for patients with recurrent er /her2- breast cancer: 2023 best of breast
-
22:57
2022 west oncology conference | breast cancers | metastatic
-
0:30
new classifications and staging in breast cancer | jodi widner, md | esmo22 colorado
-
1:09
the exciting new field of her2-low breast cancer
-
30:57
treatment updated for her2 positive breast cancer: changing paradigms
-
2:02
asco22 metastatic breast cancer updates | lee schwartzberg, md | renown institute for cancer
-
1:57
a flurry of new drug development and approvals in breast cancer: 2022 esmo florida
-
1:40
her2-low is not a distinct subtype in inflammatory breast cancer
-
0:52
defining her2-low breast cancer as a clinical subtype